Anne Messer

6.2k total citations
110 papers, 4.8k citations indexed

About

Anne Messer is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Neurology. According to data from OpenAlex, Anne Messer has authored 110 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Cellular and Molecular Neuroscience, 58 papers in Molecular Biology and 29 papers in Neurology. Recurrent topics in Anne Messer's work include Genetic Neurodegenerative Diseases (39 papers), Neuroscience and Neuropharmacology Research (24 papers) and Neurological diseases and metabolism (16 papers). Anne Messer is often cited by papers focused on Genetic Neurodegenerative Diseases (39 papers), Neuroscience and Neuropharmacology Research (24 papers) and Neurological diseases and metabolism (16 papers). Anne Messer collaborates with scholars based in United States, United Kingdom and Canada. Anne Messer's co-authors include Kevin Manley, David C. Butler, Lorraine Flaherty, Thomas L. Shirley, Joseph E. Mazurkiewicz, Chun Hui Zhou, Todd W. Miller, Michael R. Sierks, Julie A. Plummer and Abigail Snyder‐Keller and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Genetics.

In The Last Decade

Anne Messer

110 papers receiving 4.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anne Messer United States 41 2.9k 2.3k 1.0k 824 644 110 4.8k
James Garbern United States 39 2.2k 0.8× 1.4k 0.6× 612 0.6× 296 0.4× 486 0.8× 78 4.2k
Concepción Lillo United States 30 2.9k 1.0× 972 0.4× 548 0.5× 940 1.1× 952 1.5× 72 4.5k
Mark A. Marchionni United States 38 2.7k 1.0× 2.1k 0.9× 429 0.4× 300 0.4× 417 0.6× 51 5.3k
Dionisio Martín‐Zanca Spain 36 5.0k 1.7× 3.7k 1.6× 525 0.5× 438 0.5× 681 1.1× 53 8.4k
Peter E. Braun Canada 30 2.1k 0.7× 1.3k 0.6× 429 0.4× 370 0.4× 386 0.6× 64 3.8k
Gerardo Morfini United States 47 3.2k 1.1× 2.6k 1.1× 1.6k 1.5× 2.5k 3.0× 2.0k 3.1× 77 6.8k
Kelly R. Monk United States 34 2.0k 0.7× 1.6k 0.7× 392 0.4× 252 0.3× 565 0.9× 69 3.9k
Abigail S. Hackam United States 34 3.1k 1.1× 2.3k 1.0× 626 0.6× 222 0.3× 313 0.5× 76 4.2k
Ann H. Milam United States 48 6.0k 2.1× 2.7k 1.2× 333 0.3× 266 0.3× 618 1.0× 84 7.9k
Douglas L. Falls United States 20 2.0k 0.7× 1.7k 0.7× 192 0.2× 250 0.3× 565 0.9× 23 3.7k

Countries citing papers authored by Anne Messer

Since Specialization
Citations

This map shows the geographic impact of Anne Messer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Messer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Messer more than expected).

Fields of papers citing papers by Anne Messer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Messer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Messer. The network helps show where Anne Messer may publish in the future.

Co-authorship network of co-authors of Anne Messer

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Messer. A scholar is included among the top collaborators of Anne Messer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Messer. Anne Messer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Butler, David, et al.. (2018). Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model. npj Parkinson s Disease. 4(1). 25–25. 74 indexed citations
2.
Larrick, James W., Jamie K. Scott, Paul W.H.I. Parren, et al.. (2016). Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11–15, 2016, San Diego, CA. mAbs. 8(8). 1425–1434. 2 indexed citations
3.
Joshi, Shubhada N., David C. Butler, & Anne Messer. (2012). Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. mAbs. 4(6). 686–693. 58 indexed citations
4.
Messer, Anne, et al.. (2010). Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease. Neurobiology of Disease. 40(1). 130–134. 18 indexed citations
5.
Messer, Anne, Sandra Lynch, & David C. Butler. (2009). Developing intrabodies for the therapeutic suppression of neurodegenerative pathology. Expert Opinion on Biological Therapy. 9(9). 1189–1197. 25 indexed citations
6.
Miller, Todd W. & Anne Messer. (2005). Intrabody applications in neurological disorders: progress and future prospects. Molecular Therapy. 12(3). 394–401. 56 indexed citations
7.
8.
Colby, David W., Ginger Chao, Jack M. Webster, et al.. (2004). Development of a Human Light Chain Variable Domain (VL) Intracellular Antibody Specific for the Amino Terminus of Huntingtin via Yeast Surface Display. Journal of Molecular Biology. 342(3). 901–912. 84 indexed citations
9.
Zhou, Chun Hui, Sharareh Emadi, Michael R. Sierks, & Anne Messer. (2004). A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed α-synuclein. Molecular Therapy. 10(6). 1023–1031. 94 indexed citations
10.
Bolivar, Valerie J., et al.. (2002). The development of behavioral abnormalities in the motor neuron degeneration (mnd) mouse. Brain Research. 937(1-2). 74–82. 43 indexed citations
11.
Murphy, Robert C. & Anne Messer. (2001). Gene Transfer Methods for CNS Organotypic Cultures: A Comparison of Three Nonviral Methods. Molecular Therapy. 3(1). 113–121. 44 indexed citations
12.
Dalpé, Gratien, Nicole Leclerc, Anne Messer, et al.. (1998). Dystonin Is Essential for Maintaining Neuronal Cytoskeleton Organization. Molecular and Cellular Neuroscience. 10(5-6). 243–257. 91 indexed citations
13.
Porter, Joanne C., Anne Messer, & Alan Peterson. (1997). The Motor Neuron Degeneration (mnd) Gene Acts Intrinsically in Motor Neurons and Peripheral Fibroblasts. Molecular and Cellular Neuroscience. 9(3). 185–193. 4 indexed citations
14.
Porter, Joanne C. & Anne Messer. (1996). Genetic mapping of farnesyltransferase alpha(Fnta) to mouse Chromosome 8. Mammalian Genome. 7(8). 622–623. 1 indexed citations
15.
Messer, Anne, et al.. (1992). Mapping of the motor neuron degeneration (Mnd) gene, a mouse model of amyotrophic lateral sclerosis (ALS). Genomics. 13(3). 797–802. 55 indexed citations
16.
Callahan, Linda M., Esther L. Wylen, Anne Messer, & Joseph E. Mazurkiewicz. (1991). Neurofilament Distribution is Altered in the Mnd (Motor Neuron Degeneration) Mouse. Journal of Neuropathology & Experimental Neurology. 50(4). 491–504. 40 indexed citations
17.
Messer, Anne, et al.. (1990). Staggerer Mutant Mouse Purkinje Cells Do Not Contain Detectable Calmodulin mRNA. Journal of Neurochemistry. 55(1). 293–302. 40 indexed citations
18.
Wuenschell, Carol, Anne Messer, & Allan J. Tobin. (1990). Lurcher purkinje cells express glutamic acid decarboxylase and calbindin mRNAs. Journal of Neuroscience Research. 27(1). 65–70. 10 indexed citations
19.
Messer, Anne. (1988). Thyroxine Injections Do Not Cause Premature Induction of Thymidine Kinase in sg/sg Mice. Journal of Neurochemistry. 51(3). 888–891. 18 indexed citations
20.
Brugge, Joan S., Ana Lustig, & Anne Messer. (1987). Changes in the pattern of expression of pp60c‐src in cerebellar mutants of mice. Journal of Neuroscience Research. 18(4). 532–538. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James Garbern Breakdown of academic impact, for papers by Concepción Lillo Breakdown of academic impact, for papers by Mark A. Marchionni Breakdown of academic impact, for papers by Dionisio Martín‐Zanca Breakdown of academic impact, for papers by Peter E. Braun Breakdown of academic impact, for papers by Gerardo Morfini Breakdown of academic impact, for papers by Kelly R. Monk Breakdown of academic impact, for papers by Abigail S. Hackam Breakdown of academic impact, for papers by Ann H. Milam Breakdown of academic impact, for papers by Douglas L. Falls
Rankless by CCL
2026